Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2025-04-16 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, the total amount spent, the price range, and the purpose of the repurchase (conversion of convertible bonds). It references previous announcements and reports related to the repurchase plan but itself is a progress update on the share buyback activity. The document length is 1582 characters, which is relatively short and focused on the repurchase activity rather than a full financial report or other types of filings. Therefore, this document fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2025-04-16 Chinese
奥锐特药业股份有限公司关于“奥锐转债”预计满足转股价格修正条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from 奥锐特药业股份有限公司 regarding the expected triggering of a convertible bond's (奥锐转债) conversion price adjustment condition. It details the terms of the convertible bond issuance, the conditions under which the conversion price may be adjusted downward, and the procedural steps following such a trigger. The document includes regulatory references, bond codes, issuance dates, and risk warnings. It is not a full financial report, audit, or earnings release, but rather a specific update on convertible bond terms and potential price adjustments. This fits the category of a Capital/Financing Update (CAP), as it relates to financing instruments and their terms. The document length is under 5,000 characters and contains substantive information about the convertible bond terms and potential price adjustment, not merely an announcement of a report publication or a regulatory filing. Therefore, the best classification is CAP with high confidence.
2025-04-14 Chinese
奥锐特药业股份有限公司关于变更持续督导保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for a convertible bond issuance project by 奥锐特药业股份有限公司. It details the replacement of a sponsor representative due to work changes and confirms that the change does not affect previously issued opinions or documents. The document is short (916 characters) and focuses on management and regulatory compliance related to bond issuance supervision, not on financial results, audit, or detailed reports. This fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about a sponsor representative change for a financing project, not a full capital/financing update or management change announcement per se.
2025-04-14 Chinese
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of cash management using part of idle raised funds by the company 奥锐特药业股份有限公司. It details the use of idle raised funds for cash management, including investment in structured deposits, approval by the board, risk disclosures, and references to previous announcements. The document is relatively short (3243 characters) and focuses on the update of cash management activities rather than presenting a full financial report or detailed financial statements. It is not an annual or interim report, earnings release, or audit report. It is also not a regulatory certification or officer attestation. The document fits the category of Capital/Financing Update (CAP) as it provides updates on the company's use of raised funds and cash management activities related to financing and capital usage.
2025-04-09 Chinese
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理到期赎回公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the use of idle raised funds for cash management and the redemption of a structured deposit product. It includes details about board approval, amounts involved, and dates. The document is short (850 characters) and focuses on a specific financing activity rather than a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-04-08 Chinese
奥锐特药业股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, the price range, the total amount spent, and the purpose of the repurchase (conversion of convertible bonds). It references regulatory rules about share repurchases and provides updates on the repurchase progress as of a specific date. The document is not a full financial report, earnings release, or management discussion, but a specific update on share buyback activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on repurchase progress, confirming it is not a report publication or regulatory filing. Confidence is high due to clear content and context.
2025-04-01 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.